A Phase I/II Study of PI3Kγδ Inhibitor Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma Who Have Progressed on Anti-PD1 Therapy
Latest Information Update: 14 May 2024
At a glance
- Drugs Duvelisib (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 08 May 2024 Planned End Date changed from 1 Oct 2028 to 1 Oct 2029.
- 08 May 2024 Planned primary completion date changed from 1 Apr 2027 to 1 Apr 2028.
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology